Ocular Therapeutix Inc (NASDAQ: OCUL) kicked off on Tuesday, up 0.33% from the previous trading day, before settling in for the closing price of $9.01. Over the past 52 weeks, OCUL has traded in a range of $2.00-$11.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 121.20%. While this was happening, its average annual earnings per share was recorded -16.21%. With a float of $135.49 million, this company’s outstanding shares have now reached $155.92 million.
Let’s determine the extent of company efficiency that accounts for 267 employees. In terms of profitability, gross margin is 90.81%, operating margin of -187.94%, and the pretax margin is -227.16%.
Ocular Therapeutix Inc (OCUL) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 13.10%, while institutional ownership is 76.73%. The most recent insider transaction that took place on Aug 23 ’24, was worth 16,525. In this transaction Chief Strategy Officer of this company sold 1,832 shares at a rate of $9.02, taking the stock ownership to the 176,194 shares. Before that another transaction happened on Aug 23 ’24, when Company’s See Remarks sold 20,880 for $9.02, making the entire transaction worth $188,338. This insider now owns 812,473 shares in total.
Ocular Therapeutix Inc (OCUL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -16.21% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Take a look at Ocular Therapeutix Inc’s (OCUL) current performance indicators. Last quarter, stock had a quick ratio of 16.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.35, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Looking closely at Ocular Therapeutix Inc (NASDAQ: OCUL), its last 5-days average volume was 0.9 million, which is a drop from its year-to-date volume of 2.11 million. As of the previous 9 days, the stock’s Stochastic %D was 76.88%. Additionally, its Average True Range was 0.45.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 93.43%, which indicates a significant increase from 77.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.68% in the past 14 days, which was lower than the 82.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.69, while its 200-day Moving Average is $6.30. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $9.17. Second resistance stands at $9.29. The third major resistance level sits at $9.48. If the price goes on to break the first support level at $8.86, it is likely to go to the next support level at $8.67. Should the price break the second support level, the third support level stands at $8.55.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
The company with the Market Capitalisation of 1.41 billion has total of 154,889K Shares Outstanding. Its annual sales at the moment are 58,440 K in contrast with the sum of -80,740 K annual income. Company’s last quarter sales were recorded 16,440 K and last quarter income was -43,780 K.